These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35172721)

  • 21. Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials.
    Yu J; Mehran R; Clayton T; Gibson CM; Brodie BR; Witzenbichler B; Lincoff AM; Deliargyris EN; Gersh BJ; Pocock SJ; Stone GW; Dangas GD
    Catheter Cardiovasc Interv; 2016 Feb; 87(3):391-400. PubMed ID: 26624854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.
    Taylor LA; Mauro VF
    Ann Pharmacother; 2012 Jan; 46(1):35-41. PubMed ID: 22170973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of worsening renal dysfunction on the comparative efficacy of bivalirudin and platelet glycoprotein IIb/IIIa inhibitors: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
    Perdoncin E; Zhang M; Riba A; LaLonde TA; Grines CL; Gurm HS
    Circ Cardiovasc Interv; 2013 Dec; 6(6):688-93. PubMed ID: 24280966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
    Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Shah RM; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
    JACC Cardiovasc Interv; 2016 Dec; 9(23):2376-2386. PubMed ID: 27838271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
    Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
    J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
    Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
    Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.
    Abtahian F; Waldo S; Jang IK
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):390-6. PubMed ID: 25753749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study.
    Kaul U; Dua A; Sethi AK; Arambam P; Seth A
    Indian Heart J; 2015; 67(4):311-7. PubMed ID: 26304562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention.
    Xiang DC; Gu XL; Song YM; Huang WJ; Tang LQ; Yin YH; Geng SH; Zhou H; Fan WM; Hu R; Pan CM; Zhang Y; Xiao FY; Wan HB; Liu ZZ
    Chin Med J (Engl); 2013 Aug; 126(16):3064-8. PubMed ID: 23981613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.
    Deshpande NV; Pratiti R; Admane P; Mukherjee D; Mardikar HM
    Indian Heart J; 2012; 64(5):444-8. PubMed ID: 23102380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bivalirudin use and one-month outcome in the context of contemporary antiplatelet treatment: insights from the Greek Antiplatelet Registry.
    Alexopoulos D; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Karayannis G; Angelidis C; Stavrou K; Vavuranakis M; Goudevenos JA; Stefanadis C;
    Cardiovasc Ther; 2014 Jun; 32(3):120-6. PubMed ID: 24512682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Independent predictors of bleeding complications in patients undergoing PCI with concomitant treatment with bivalirudin in clinical practice results from the ImproveR registry.
    Koeth O; Gulba D; Huber K; Madsen JK; Darius H; Schneider S; Zeymer U;
    J Cardiovasc Pharmacol; 2013 Dec; 62(6):507-11. PubMed ID: 24072173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of bivalirudin in patients with coronary artery disease.
    Abdel-Wahab M; Richardt G
    Expert Opin Drug Saf; 2012 Jan; 11(1):141-50. PubMed ID: 21999110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
    BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention.
    MacHaalany J; Abdelaal E; Bataille Y; Plourde G; Duranleau-Gagnon P; Larose É; Déry JP; Barbeau G; Rinfret S; Rodés-Cabau J; De Larochellière R; Roy L; Costerousse O; Bertrand OF
    Am J Cardiol; 2012 Dec; 110(12):1742-8. PubMed ID: 22980964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
    Pinto DS; Kohli P; Fan W; Kirtane AJ; Kociol RD; Meduri C; Deliargyris EN; Prats J; Reynolds MR; Stone GW; Michael Gibson C
    Catheter Cardiovasc Interv; 2016 Feb; 87(3):363-73. PubMed ID: 26011467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials.
    Verdoia M; Barbieri L; Parodi G; Bellandi B; Schaffer A; Suryapranata H; De Luca G
    Catheter Cardiovasc Interv; 2017 Oct; 90(4):553-565. PubMed ID: 28471057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
    Tavano D; Visconti G; D'Andrea D; Focaccio A; Golia B; Librera M; Caccavale M; Ricciarelli B; Briguori C
    Am J Cardiol; 2009 Nov; 104(9):1222-8. PubMed ID: 19840566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Of Bleeding Avoidance Strategies with age-related bleeding and In-hospital mortality in patients undergoing percutaneous coronary Interventions.
    Khambatta S; Othman H; Seth M; Lalonde T; Rosman HS; Gurm HS; Mehta RH;
    Cardiovasc Revasc Med; 2016 Jun; 17(4):233-40. PubMed ID: 26994504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.